PLP 182-196: TCQSIAFPSKTSASI (SEQ ID NO. 12)

PLP183-197: CQSIAFPSKTSASIG (SEQ ID NO. 13)

PLP 184-198: QSIAFPSKTSASIGS (SEQ ID NO. 14)

PLP 208-222: VLPWNAFPGKVCGSN (SEQ ID NO. 15)

PLP 36-61: HEALTGTEKLIETYFSKNYQDYEYLI (SEQ ID NO. 1)

PLP 179-206: TWTTCQSIAFPSKTSASIGSLCADARMY (SEQ ID NO. 2) and

PLP 207-234: GVLPWNAFPGKVCGSNLLSICKTAEFQM (SEQ ID NO. 3).

In a second aspect there is provided a peptide according to the first aspect of the invention for use in the treatment and/or prevention of a demyelinating disease.

In a third aspect, the present invention provides a pharmaceutical composition comprising one or more peptide(s) according to the first aspect of the invention.

~~In a fourth aspect the present invention provides~~Also disclosed is a method for treating and/or preventing a demyelinating disease in a subject in need of same which comprises the step of administering a peptide according to the first aspect of the invention to the subject.

In a ~~fifth~~ fourth aspect, the present invention relates to the use of a peptide according to the first aspect of the invention in the manufacture of a medicament for use in the prevention and/or treatment of a demyelinating disease.

In connection with the second, and fourth ~~and fifth~~ aspects of the invention, the disease may be multiple sclerosis.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 - **Figure 1:** Three PLP peptide regions respond *in vitro* and *in vivo* and the response correlates to the DR2 binding prediction. A, represents in broad outline the binding prediction of the PLP peptides to HLA-DRB1*1501 in silico (IEDB and NetMHCII methods) and the ability of these peptides to induce a proliferative response in these mice. B and C represents the ability of 4 of these long peptides to induce EAE (2 individual experiments).

4. A peptide according to any preceding claim, for use in the treatment and/or prevention of a demyelinating disease.

5. A peptide according to claim 4, wherein the disease is multiple sclerosis.

6. A pharmaceutical composition comprising one or more peptide according to any of claims 1 to 5.

~~7. A method for treating and/or preventing a demyelinating disease in a subject in need of same which comprises the step of administering a peptide according to any of claims 1 to 5 to the subject.~~

~~8. A method according to claim 7, wherein the disease is multiple sclerosis.~~

~~9~~7. The use of a peptide according to any of claims 1 to 5 in the manufacture of a medicament for use in the prevention and/or treatment of a demyelinating disease.

~~10~~8. The use according to claim ~~9~~7, wherein the disease is multiple sclerosis.